Stock Events

Stock Events

Percheron Therapeutics 

$0.002400
7
-$0.00-4% Thursday 13:45

Statistics

Day High
0.0024
Day Low
0.0024
52W High
0.0115
52W Low
0.0011
Volume
55,000
Avg. Volume
2,808
Mkt Cap
3.65M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jul 21
$0.09
Nov 20
$0.04
Jul 20
$0.07
Nov 19
$0.03
Jul 19
$0.06
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

19AugExpected
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.01
-0.01
-0
-0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-3.24MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PERCF. It's not an investment recommendation.
Neuren Pharmaceuticals
3
NEU.AU
Alterity Therapeutics
3
ATH.AU
Moleculin Biotech
2
MBRX
Mexedia S.P.A
2
ALMEX.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is a key competitor in the cystic fibrosis market, directly competing with Percheron Therapeutics' treatments in this area.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie competes in multiple therapeutic areas including immunology and oncology, overlapping with Percheron's research and drug development efforts.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is involved in biopharmaceuticals targeting genetic disorders, directly competing with Percheron's gene therapy projects.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics in areas like oncology and cardiovascular disease, which are also interest areas for Percheron Therapeutics.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences operates in the field of antiviral drugs, including treatments for HIV, hepatitis B, hepatitis C, and influenza, competing with Percheron's antiviral programs.
Biogen
BIIB
Mkt Cap32.28B
Biogen's focus on neurological diseases and innovative therapies places it in direct competition with Percheron's neurological drug development.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical targets rare genetic diseases, a field where Percheron is also actively developing treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals works on RNAi therapeutics, competing with Percheron's similar efforts in gene silencing technologies.
Novartis
NVS
Mkt Cap292.35B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments in areas where Percheron Therapeutics is also active, such as cardiovascular, oncology, and neurology.

About

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also develops HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed Phase I clinical trial to targer v-domain immunoglobulin suppressor of T-cell activation and cancer cells. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Show more...
CEO
James Stuart Garner
Employees
8
Country
Australia
ISIN
AU0000317281
WKN
000A3E1W6

Listings

STU
DE
AWY0.STU
MU
DE
AWY.MU
STU
DE
AWY.STU
MU
DE
AWY0.MU

0 Comments

Share your thoughts

FAQ

What is Percheron Therapeutics stock price today?▼
The current price of PERCF is $0.00 USD — it has decreased by -4% in the past 24 hours. Watch Percheron Therapeutics stock price performance more closely on the chart.
What is Percheron Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Percheron Therapeutics stocks are traded under the ticker PERCF.
Is Percheron Therapeutics stock price growing?▼
PERCF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Percheron Therapeutics has showed a -79.13% decrease.
What is Percheron Therapeutics market cap?▼
Today Percheron Therapeutics has the market capitalization of 3.65M
When is the next Percheron Therapeutics earnings date?▼
Percheron Therapeutics is going to release the next earnings report on February 24, 2027.
What is Percheron Therapeutics revenue for the last year?▼
Percheron Therapeutics revenue for the last year amounts to 0 USD.
What is Percheron Therapeutics net income for the last year?▼
PERCF net income for the last year is -3.24M USD.
How many employees does Percheron Therapeutics have?▼
As of September 05, 2026, the company has 8 employees.
In which sector is Percheron Therapeutics located?▼
Percheron Therapeutics operates in the Health & Wellness sector.
When did Percheron Therapeutics complete a stock split?▼
The last stock split for Percheron Therapeutics was on May 13, 2025 with a ratio of 11:10.
Where is Percheron Therapeutics headquartered?▼
Percheron Therapeutics is headquartered in Melbourne, Australia.